Compugen Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Feb 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 16 to 18, 2027 · next Jan 16
- 2 fees due Apr 24, 2027
- 1 fee due Aug 4, 2027The maintenance fee for PVRIG polypeptides and methods of treatment (US 10,550,173) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,714,289 | Anti-Pvrig Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 10,351,625 | Anti-Pvrig Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 11,220,542 | Anti-Pvrig Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 11,623,955 | Anti-Pvrig Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 11,795,220 | Anti-Pvrig Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,312,404 | Anti-Pvrig Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 10,227,408 | Anti-Pvrig Antibodies and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 10,550,173 | PVRIG polypeptides and methods of treatment In force · USPTO record | In force | USPTO record | |
| US 11,795,209 | PVRIG polypeptides and methods of treatment In force · USPTO record | In force | USPTO record | |
| US 10,124,061 | Anti-Tigit Antibodies, Anti-Pvrig Antibodies and Combinations Thereof In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 17: 40 lapsed for an unpaid fee · 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 35 abandoned · 29 no status recorded
Showing 1 to 10 of 74, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/190,452 | Anti-Pvrig Antibodies and Methods of Use | Apr 25, 2025 | Pending |
| 18/774,872 | Triple Combination Antibody Therapies | Jul 16, 2024 | Pending |
| 18/754,029 | IL-18BP Antagonist Antibodies and Their Use in Monotherapy and Combination Therapy in the Treatment of Cancer | Jun 25, 2024 | Pending |
| 18/460,523 | Sep 1, 2023 | No status recorded | |
| 18/460,276 | HIDE1 Compositions and Methods | Sep 1, 2023 | Abandoned |
| 18/452,985 | Anti-Tigit Antibodies, Anti-Pvrig Antibodies and Combinations Thereof | Aug 21, 2023 | Pending |
| 18/185,632 | PVRL2 And/Or Pvrig as Biomarkers for Treatment | Mar 17, 2023 | Abandoned |
| 18/846,112 | IL-18BP Antagonist Antibodies and Their Use in Monotherapy and Combination Therapy in the Treatment of Cancer | Mar 15, 2023 | Pending |
| 18/700,194 | Combination Therapy with Anti-Pvrig Antibodies Formulations, Anti-Tigit Antibodies, and ANTI-PD-1 Antibodies | Oct 17, 2022 | Pending |
| 18/572,125 | Anti-Tigit and Anti-Pvrig in Monotherapy and Combination Treatments | Jul 1, 2022 | Pending |
10 of 74 applications shown.
Pro members see all 74 published applications.